Galvani Bioelectronics, a joint venture between Verily and GSK, recently announced the first successful implantation of a neurostimulator that uses splenic nerve stimulation as an experimental therapy for rheumatoid arthritis patients.
Vagus nerve stimulation devices still have a long way to go, but the therapeutic potential of the vagus nerve, the advent of AI and machine learning in healthcare and the opportunity to establish truly personalized digital medicine are enough to warrant further exploration into VNS.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Several medical devices using electrical neuromodulation have been developed to treat pain, spinal injuries, epilepsy, migraine, and other conditions. More than just a new technological solution, the possibility presented by these devices is significant.
The Burlingame, California-based startup bills itself as a bioelectric medicine company that is using electric signals to stimulate the nervous system as a pathway to treat chronic disease.
Lux Capital led the round with participation from Andreessen Horowitz, Jazz Venture Partners, SoftTech Ventures and Xfund.